Skip to content

Investigating the effect of agomelatine and sertraline on anxiety and depression

comparing the efficiency of agomelatine & sertraline in the depression & anxiety of patients suffering from psychogenic non-epileptic seizure (PNES)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230626058586N3
Enrollment
34
Registered
2024-02-19
Start date
2024-02-19
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: anxiety. Condition 2: depression. Anxiety disorder due to known physiological condition Other depressive episodes

Interventions

Intervention 1: Intervention group: Agomelatine (25-50mg). Intervention 2: Intervention group: Sertraline (50-200 mg).

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Confirmation of PNES diagnosis by neurologist and psychiatrist Not suffering from mental disability and pregnancy Age range between 18-65 years Patient satisfaction

Exclusion criteria

Exclusion criteria: Patient's lack of consent to continue participating in the study Confirmation of neurological disorder or other major disorders in addition to anxiety and depression during study Not coming for a follow-up visit.

Design outcomes

Primary

MeasureTime frame
Depression. Timepoint: before the intervention and one month, two months and three months after the intervention. Method of measurement: Hamilton questionnaire.;Anxiety. Timepoint: before the intervention and one month, two months and three months after the intervention. Method of measurement: Hamilton questionnaire.

Secondary

MeasureTime frame
Seizure attacks. Timepoint: before the intervention and one month, two months and three months after the intervention. Method of measurement: EEG.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Vaziri Harami

Shahid Beheshti University of Medical Sciences

md.r.vaziriharami@gmail.com+98 21 7343 0300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026